NCT02133911 (RAMP-DCM) is a Phase 2 clinical trial of Ranolazine in Dilated Cardiomyopathy, sponsored by University Medical Centre Ljubljana.

Who is sponsoring NCT02133911?

NCT02133911 is sponsored by University Medical Centre Ljubljana.

What drugs are being tested in NCT02133911?

Interventions in NCT02133911: Ranolazine.

What condition does NCT02133911 study?

NCT02133911 studies Dilated Cardiomyopathy.

Is NCT02133911 still recruiting?

NCT02133911 is currently completed. Last updated 28 April 2021.

Last reviewed 2021-04-28 · How we verify

NCT02133911: RAMP-DCM

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Pilot Trial of Ranolazine to Treat Patients With Dilated Cardiomyopathy

Completed Phase 2 Last updated 28 April 2021

What this trial tests

Phase 2 trial testing Ranolazine in Dilated Cardiomyopathy in 10 participants. Completed in 2 April 2016.

Timeline

1 May 2014

Primary endpoint
15 December 2015

2 April 2016

Quick facts

Lead sponsor	University Medical Centre Ljubljana
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	10
Start date	1 May 2014
Primary completion	15 December 2015
Estimated completion	2 April 2016
Sites	1 location across Slovenia

Drugs / interventions tested

Ranolazine (RANOLAZINE) — full drug profile →

Conditions studied

Dilated Cardiomyopathy — all drugs for Dilated Cardiomyopathy →

Sponsor

University Medical Centre Ljubljana

Who can join

Adults 18 to 75, any sex, with Dilated Cardiomyopathy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Recent data suggest that areas of fibrosis and hibernating myocardium develop in patients with non ischemic dilated cardiomyopathy. Ranolazine is a new drug, developed to releave symptoms of angina in patients with stable coronary disease that is not suitable for surgical or percutaneous revascularization. It has been shown that in patients with stable coronary disease Ranolazine improves myocardial perfusion as shown with myocardial nuclear imaging. The aim of this trial is to evaluate effects of ranolazine on myocardial perfusion in patients with dilated cardiomyopathy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Ranolazine

Trials testing the same drug.

NCT04456517 — Reduce Crohn's-Associated Diarrhea With Sodium Channel Therapy · Phase 2 · terminated
NCT03401502 — A TSHRN1201 Sub-study-To Evaluate the Effects of add-on Ranolazine on Exercise Tolerance and Angina Frequency · NA · completed
NCT03486561 — Management of Ischemic Heart Disease With Angiwell-XR (Ranolazine) · Phase 4 · unknown
NCT03257683 — RANOLAZINE STUDY: Speckle Tracking Derived Myocardial Strain · withdrawn
NCT03070470 — CiPA Phase 1 ECG Biomarker Validation Study · Phase 1 · completed

Other recruiting trials for Dilated Cardiomyopathy

Currently open trials in the same condition.

NCT07241104 — A Study of AZD4063 in PLN R14del Dilated Cardiomyopathy · Phase 1 · recruiting
NCT06250257 — Bromocriptine in Dilated Cardiomyopathy Among Women of Reproductive Age · Phase 3 · recruiting
NCT06730464 — Image-Based Prediction of Ventricular Tachycardia Events in Non-ischemic Cardiomyopathy · recruiting
NCT06236022 — The Effects of Sirolimus in Patients With Dilated Cardiomyopathy Infected With Kaposi Sarcoma-associated Virus · Phase 4 · recruiting
NCT05837143 — Myocardial Telomere Recapping Study for Dilated Cardiomyopathy · EARLY_PHASE1 · active not recruiting

Other University Medical Centre Ljubljana trials

Trials by the same sponsor.

NCT07466472 — Image-Guided Central Catheter Insertion With Concurrent Assessment of Vascular Wall Integrity · not yet recruiting
NCT07446244 — Catheter Ablation of Advanced Forms of Atrial Fibrillation · NA · enrolling by invitation
NCT07109076 — Effect of Immediate Skin-to-Skin Contact on Neonatal Heart Rate Variability After Cesarean Secton · NA · recruiting
NCT07354880 — Effect of Tirzepatide on Cardiovascular and Metabolic Parameters in Obese Adult Patients With Congenital Heart Disease · Phase 4 · not yet recruiting
NCT07496736 — Post-exposure Influenza Prophylaxis in a Hospital Setting · Phase 3 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02133911 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Medical Centre Ljubljana
Last refreshed: 28 April 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02133911.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing